Proteins and metabolites defining progression from LTBI to active TB disease, response to antituberculosis treatment and treatment outcome
| Clinical question | Proteins | Metabolites | Material |
| LTBI to active TB transition | Chemokines CCL1, CCL3, CXCL1, CXCL2, CXCL9, CXCL10 [73], kallikrein 1B, C-reactive protein, haptoglobin, alpha-1-acid glycoprotein 1 haptoglobin, complement component C9, apolipoprotein A1, serotransferrin [74] | Cortisol, mannose, gamma-glutamylglutamine, cysteine, glycocholenate sulfate, phenylalanine, histidine, citrulline, glutamine, tryptophan [75] | Blood |
| Treatment response | Chemokines CCL1, CCL3, CXCL1, CXCL9 [73], nectin-life protein 2, Ephrin type-A receptor 1, gp130, beta-Ala-His dipeptidase, transforming growth factor-beta receptor III, mannose receptor C type 2, disintegrin and metalloproteinase domain-containing protein 9, cell adhesion molecule-related/downregulated by oncogenes [76] | Blood | |
| Matrix metalloproteinases MMP-2, MMP-3, MMP-8, MMP-9, tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 [77] | Sputum | ||
| Seryl-leucine core 1 O-glycosylated peptide [78] | Urine | ||
| Treatment outcome | Chemokines CCL1, CCL2, CXCL2, CXCL9, CXCL10, CXCL11 [73] | Blood | |
| Matrix metalloproteinases MMP-1, MMP-3, MMP-8, tissue inhibitor of metalloproteinases TIMP-2 [77] | Sputum | ||
| Tryptophan [79] | CSF (TB meningitis) |
LTBI: latent tuberculosis infection; TB: tuberculosis; CSF: cerebrospinal fluid.